Advertisement

Volume 131, Issue 16

 

 

April 19, 2018 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Ring1A and Ring1B maintain murine AML stem cells through repression of Glis2.
See the article by Shima et al.

A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL
Approximately half of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) do not achieve an adequate response to salvage chemotherapy to allow autologous stem cell transplantation. Sauter and colleagues report excellent response and minimal toxicity in a phase 1 study adding ibrutinib to salvage rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) chemotherapy for this patient population.


Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL
Vari et al elucidate the contribution of programmed cell death 1–positive (PD-1+) natural killer (NK) cells and programmed cell death ligand 1–positive (PD-L1+) monocyte/macrophages to immune evasion by Reed-Sternberg cells in Hodgkin lymphoma and, to a lesser degree, in DLBCL cells.


Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide
Takahashi and colleagues report on targeted sequencing of 295 cancer-associated genes in patients with treatment-naïve and relapsed/refractory chronic lymphocytic leukemia, correlating genotypic changes with response to lenalidomide.


Ring1A and Ring 1B inhibit expression of Glis2 to maintain murine MOZ-TIF2 AML stem cells
Shima and colleagues explore the pathways for maintenance of acute myelogenous leukemia (AML) stem cells, demonstrating that the polycomb repressor complex Ring1A and Ring1B support leukemia proliferation through repression of Glis2.


Hepcidin agonists as therapeutic tools
In a Blood Spotlight, Casu et al review the potential of hepcidin agonist agents in treating iron overload syndromes.


Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset
Hülsdünker and colleagues reveal an unexpected role of neutrophils as antigen-presenting cells in the initiation of graft-versus-host disease.


Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT
Berger et al further elucidate the relationship between pre-existing clonal hematopoiesis of indeterminate potential and the development of therapy-related myeloid neoplasm (tMN) following autologous stem cell transplant and demonstrate that tMN originates in stem cells bearing mutations that are present years before disease onset.


Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents
In this Perspective, Xu et al discuss the nonhemostatic role of platelets in reinforcing tumor growth and metastasis through proliferative signals, antiapoptotic effects, and proangiogenic factors.

 

View this week's complete table of contents

Why Submit to Blood?

 


Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.